MedPath

Effects of Vitamin D Fortification on Vitamin D Metabolite Profiles and Status in Vitamin D Insufficient Individuals

Phase 1
Withdrawn
Conditions
Vitamin D Deficiency
Registration Number
NCT02422784
Lead Sponsor
University of Manitoba
Brief Summary

This is a cross-sectional study designed to compare plasma/serum and urine vitamin D metabolite profiles of vitamin D sufficient and insufficient individuals.

There are two phases of this study.

Phase 1 - Consented study participants will attend a screening visit and provide a fasting blood and urine sample. Those individuals who are vitamin D insufficient based on serum 25(OH)D concentrations will be invited to participate in Phase II

Phase II - is a double-blind, randomized, control study designed to examine vitamin D status in vitamin D insufficient individuals consuming a water-soluble form of vitamin D3. Eligible participants will be asked to consume one of three beverages: i) rooibos iced-tea (control); ii) rooibos iced-tea fortified with 1000 IU of water-soluble vitamin D3; or iii) rooibos iced-tea fortified with 1000 IU of water-soluble vitamin D3 and 360 mg calcium at 240 mL of iced-tea consumed daily for 6 weeks. Participants will attend 6 weekly visits following baseline and provide a fasting blood sample for assessment of serum 25(OH)D concentrations.

Objectives: 1) To investigate plasma/serum and urine vitamin D metabolite profiles in vitamin D sufficient and insufficient individuals; and 2) To determine the effects of vitamin D3 fortification on serum 25-dihydroxy-vitamin D \[25(OH)D\] concentrations, markers of vitamin D and calcium metabolism, and vitamin D metabolite profile in plasma/serum and urine of vitamin D insufficient individuals.

Detailed Description

Health individuals from the general public will be recruited into this cross-sectional study designed to compare plasma/serum and urine vitamin D metabolite profiles of those identified as vitamin D sufficient and insufficient individuals.

There are two objectives:

Objective 1: To investigate plasma/serum and urine vitamin D metabolite profiles in vitamin D sufficient and insufficient individuals; N=20 and will consist of 10 individuals identified as vitamin D insufficient and 10 individuals identified as vitamin D deficient individuals.

Objective 2: To determine the effects of vitamin D3 fortification on serum 25-dihydroxy-vitamin D \[25(OH)D\] concentrations, markers of vitamin D and calcium metabolism, and vitamin D metabolite profile in plasma/serum and urine of vitamin D insufficient individuals. N=45.

To achieve the objectives, the study will be conducted in two phases:

Phase 1 - Healthy males or females, ≥19 and ≤50 years of age, will be recruited from the general public. Consented study participants will provide a fasting blood and urine sample for the purpose of determination of vitamin D status (insufficient vs. deficient) based on serum 25(OH)D concentrations. Forty-five (45) individuals identified as vitamin D insufficient (having a serum 25(OH)D concentration ≥30 and ≤75 nmol/L) will proceed to phase II. A N=20 (10 vitamin D insufficient and 10 vitamin D deficient) will also be identified to satisfy objective 1.

Phase II - is a double-blind, randomized, control study designed to examine vitamin D status in vitamin D insufficient individuals consuming a water-soluble form of vitamin D3. Eligible participants will randomized to consume one of three beverages: i) rooibos iced-tea (control); ii) rooibos iced-tea fortified with 1000 IU of water-soluble vitamin D3; or iii) rooibos iced-tea fortified with 1000 IU of water-soluble vitamin D3 and 360 mg calcium at 240 mL of iced-tea consumed daily for 6 weeks. Both researchers and participants will be blinded to the beverage group assigned to each participant. Participants will then attend 6 weekly visits following the baseline visit to provide fasting blood samples for assessment of serum 25(OH)D concentrations.

Analysis of intact-PTH, alkaline-phosphatase, calcium, phosphorus, CRP, TAP and vitamin D metabolite profile and a urine sample will also be obtained for assessment of N-telopeptide and vitamin D metabolite profile will also occur at Baseline and Week 6. Fasting blood samples collected at week 3 will be used for additional assessment of serum alkaline phosphatase, calcium and phosphorus. A 3-day Food Record will be provided at week 3.

Vitamin D insufficient participants will be stratified according to their serum 25(OH)D concentrations (≥30 and ≤50, or \>50 and ≤75 nmol/L) after screening and prior to the beverage study to ensure that a range of lower and higher serum 25(OH)D concentrations are represented in each beverage group.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

A. Inclusion Criteria for Objective 1 (Part One):

  1. Adult volunteers, male or female, between 19 and 50 years of age;
  2. Body mass index (BMI) ≥20 and ≤30 kg/m2 (normal to overweight);
  3. Must be on a stable regime for the past three months, if taking vitamin and mineral/dietary/herbal supplements; and
  4. Willing to provide informed consent.

B. Inclusion Criteria for Objective 2 (Part Two):

  1. Adult volunteers, male or female, between 19 and 50 years of age;
  2. Body mass index (BMI) ≥20 and ≤30 kg/m2 (normal to overweight);
  3. Must be on a stable regime for the past three months, if taking vitamin and mineral/dietary/herbal supplements;
  4. Vitamin D insufficient (serum 25(OH)D concentrations ≥30 and ≤75 nmol/L);
  5. Willing to comply with protocol requirements; and
  6. Willing to provide informed consent.
Exclusion Criteria
  1. Take a vitamin D or calcium supplement within the last three months before the start date of the study, or during the study;
  2. History of vitamin D deficiency (serum 25(OH)D concentration <30 nmol/L);
  3. History of hypocalcaemia;
  4. Presence of a clinically diagnosed disease affecting the circulatory, respiratory, immune, skeletal, urinary, muscular, endocrine, digestive, nervous or reproductive system that requires medical treatment;
  5. Taking any medication (with the exception of birth control);
  6. Daily consumption of more than three servings of dairy products;
  7. Undergone significant sun exposure one month before start date of the study;
  8. Use or have used a tanning booth one month before start date of the study, or during the study;
  9. Plan to travel to a sunny climate during the study;
  10. Currently smoking or have smoked within the last six months before start date of the study, or during the study;
  11. Have allergies to tea products;
  12. Pregnant or lactating; and
  13. Consume excessive alcohol (>10 drinks/week for women, >15 drinks/week for men).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Plasma/Serum and Urine Vitamin D Metabolite Profiles of Vitamin D Sufficient and Insufficient IndividualsScreening Visit (Day 0) - Phase 1

To investigate plasma/serum and urine vitamin D metabolite profiles in vitamin D sufficient and insufficient individuals.

The Effects of Vitamin D Fortification on Serum 25(OH)D in Vitamin D Insufficient Individuals.6 Weeks (Phase II)

To determine the effects of 6 weeks of vitamin D3 fortification on serum 25-dihydroxy-vitamin D \[25(OH)D\] concentrations of vitamin D insufficient individuals.

Secondary Outcome Measures
NameTimeMethod
The Effects of vitamin D3 Fortification on calcium metabolism of Vitamin D Insufficient Individuals.6 Weeks (Phase II)

To determine the effects of 6 weeks of vitamin D3 fortification on calcium metabolism in plasma/serum and urine of vitamin D insufficient individuals.

The Effects of Vitamin D3 Fortification on Vitamin D Metabolite Profile of Vitamin D Insufficient Individuals.6 Weeks (Phase II)

Determine the effects of vitamin D3 fortification on the vitamin D metabolite profile in plasma/serum and urine of vitamin D insufficient individuals.

The Effects of Vitamin D3 Fortification on markers of vitamin D of vitamin D insufficient individuals6 Weeks (Phase II)

To determine the effects of 6 weeks of vitamin D3 fortification on markers of vitamin D in plasma/serum and urine of vitamin D insufficient individuals.

Trial Locations

Locations (1)

St. Boniface Hospital, Asper Clinical Research Institute

🇨🇦

Winnipeg, Manitoba, Canada

St. Boniface Hospital, Asper Clinical Research Institute
🇨🇦Winnipeg, Manitoba, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.